The activity of tyrosine kinase inhibitors on clear cell renal cell carcinoma tumor initiating cells in hypoxic microenvironment
Preexisting hypertension is associated with advanced tumor stage but improved cancer specific survival in clear cell renal cell carcinoma
Tumor suppressor screens of 3p chromatin modulators link BAP1 mutations to poor clinical outcomes in clear cell renal cell carcinoma
Hereditary and sporadic type 2 papillary renal cell carcinoma converge at NRF2 activation phenotype
Improved outcomes with sunitinib alternative schedule compared to traditional schedule: a single-center retrospective review
Isolation of renal cell carcinoma cells from blood samples using the vertical immiscible filtration assisted by surface tension (VerIFAST) microfluidic platform
Pathologic validation of renal cell carcinoma histology in the surveillance, epidemiology, and end results program
Succinate dehydrogenase kidney cancer (SDH-RCC): an aggressive example of the Warburg effect in cancer
Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC)
Tivozanib pharmacokinetic (PK)/ pharmacodynamic (PD) analysis of blood pressure and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma (RCC)
Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC)
Predictive factors of progression free survival (PFS) and overall survival (OS) in patients treated with tirosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (A-RCC): a retrospective analysis of a mono-institutional series
A phase 1 study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma
Examining everolimus in a study of tuberous sclerosis complex (TSC) trial (EXIST-2): updated safety results
B7H1 expression and association with clinical response to sunitinib therapy in metastatic renal cell carcinoma (mRCC) patients
Cardiology co-management improves blood pressure control in patients with anti-VEGF-induced hypertension
Urine biomarkers to diagnose renal cell carcinoma
Detection of circulating tumor cells in advanced renal cell carcinoma patients using microfilter-based capture
Inhibitory effects of pyrrole-imidazole polyamide targeting MMP9 for invasiveness of renal carcinoma cells
Precision of excision/reconstruction and recovery from ischemia: quality parameters for functional recovery after partial nephrectomy
Role of stereotactic body radiotherapy in the management of non-surgical patients
Association of renal cell carcinoma (RCC) and hematological malignancy (HM)
Critical analysis of frozen section deep parenchymal margin sampling during robot-assisted laparoscopic partial nephrectomy
Next-generation sequencing reveals genomic determinants of long-term response to mTOR inhibitors in patients with advanced RCC
Identification of protein expression signatures in clear renal cell carcinoma histological type
Profiling signaling pathways in formalinfi xed and paraffin-embedded renal cell carcinoma tissues
The functional role of CA9 and glucose transporters (GLUT) in human renal cell carcinoma
Clinicopathological feature of T2b renal cell carcinoma
Treatment patterns in metastatic renal cell carcinoma in the US: a retrospective chart review in community oncology practices
Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a Phase III randomized, open-label, multicenter trial
Role of PPARα in proliferation and cell cycle regulation in human renal cell carcinoma
Open-label phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (mRCC)
The lipid metabolomic profile of clear cell renal cell carcinoma (CCRCC)
Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma
Detailed comparison of the safety of tivozanib versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a Phase III trial
Identifying SETD2 -epigenetically regulated pathways to target kidney cancer metastases
Number of sites of metastases solely predicts survival of cytoreductive nephrectomy for metastatic renal cell carcinoma: revisiting lessons learned from the past
Modulation of TRiC/CCT and proteasome regulates VHL proteostasis and functionality
A description of the surgical experience in children, adolescents and young adults with renal cell carcinoma: a report from the Children's Oncology Group Study AREN 03B2
Epidemiology and characterization of pediatric and adolescent renal cell carcinoma: a report from the Children's Oncology Group Study AREN 03B2
Small sized clear cell typed renal cell carcinoma with liver, lung, bone and bone marrow metastasis
Percutaneous biopsy of kidney tumors at Roswell Park Cancer Institute (RPCI)
Ovarian and thyroid metastases from renal cell carcinoma (RCC) successfully treated with metastectomy